XETRA - Delayed Quote EUR

Darwin AG (7V0.DE)

28.20
0.00
(0.00%)
At close: May 14 at 5:36:14 PM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
Total Revenue
18,169.02
18,169.02
218,711.73
111,321.48
Cost of Revenue
12,135.08
12,135.08
90,505.06
55,739.38
Gross Profit
6,033.94
6,033.94
128,206.67
55,582.10
Operating Expense
14,596.53
14,596.53
69,045.89
26,072.90
Operating Income
-8,562.59
-8,562.59
59,160.79
29,509.20
Net Non Operating Interest Income Expense
1,506.61
1,506.61
207.10
-7.53
Pretax Income
3,018.93
3,018.93
59,724.24
29,532.40
Tax Provision
2,979.22
2,979.22
16,849.35
7,943.80
Net Income Common Stockholders
39.71
39.71
45,074.89
19,388.60
Diluted NI Available to Com Stockholders
39.71
39.71
45,074.89
19,388.60
Basic EPS
15.02
0.01
15.02
6.46
Diluted EPS
15.02
0.01
15.02
6.46
Basic Average Shares
3,000.99
3,971.30
3,000.99
3,001.33
Diluted Average Shares
3,000.99
3,971.30
3,000.99
3,001.33
Total Operating Income as Reported
-3,743.39
-3,743.39
65,051.07
29,658.38
Total Expenses
26,731.61
26,731.61
159,550.94
81,812.28
Net Income from Continuing & Discontinued Operation
39.71
39.71
42,874.89
21,588.60
Normalized Income
-8,523.97
-8,523.97
42,619.08
21,566.14
Interest Income
1,789.53
1,789.53
235.52
41.84
Interest Expense
282.92
282.92
28.42
49.37
Net Interest Income
1,506.61
1,506.61
207.10
-7.53
EBIT
3,301.85
3,301.85
59,752.66
29,581.78
EBITDA
13,472.54
13,472.54
73,412.54
30,235.99
Reconciled Cost of Revenue
12,135.08
12,135.08
90,505.06
55,739.38
Reconciled Depreciation
2,186.86
2,186.86
1,927.80
553.41
Net Income from Continuing Operation Net Minority Interest
39.71
39.71
42,874.89
21,588.60
Total Unusual Items Excluding Goodwill
10,074.92
10,074.92
356.35
30.73
Total Unusual Items
10,074.92
10,074.92
356.35
30.73
Normalized EBITDA
3,397.62
3,397.62
73,056.19
30,205.26
Tax Rate for Calcs
0
0
0
0
Tax Effect of Unusual Items
1,511.24
1,511.24
100.53
8.27
12/31/2021 - 8/2/2023

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

88Q.DE 4basebio PLC
13.00
0.00%
 
BIO.DE Biotest Aktiengesellschaft
42.60
-0.47%
 
NVV1.DE Novavax, Inc.
7.85
-0.53%
 
BIO3.DE Biotest Aktiengesellschaft
30.00
0.00%
 
9VC.DE Atai Life Sciences N.V.
1.2630
+0.44%
 
AYJ.DE Valneva SE
2.9200
+0.14%
 
VX1.DE Vertex Pharmaceuticals Incorporated
372.85
-4.85%
 
HPHA.DE Heidelberg Pharma AG
3.1200
-1.58%
 
NP5.DE Newron Pharmaceuticals S.p.A.
8.84
+2.08%
 
BBZA.DE BB Biotech AG Ord
30.15
-1.95%